Abstracts tagged "Microscopic Polyangiitis"

Abstract Number: 0526 • ACR Convergence 2022
Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial
Lynn Fussner¹, Luis Felipe Flores-Suarez², Rodrigo Cartin-Ceba³, Ulrich Specks³, P. Gerard Cox⁴, David Jayne⁵, Peter Merkel⁶ and Michael Walsh⁴, ¹The Ohio State University, Columbus, OH, ²Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, ³Mayo Clinic, Rochester, MN, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
Abstract Number: 0527 • ACR Convergence 2022
Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials
Florence Delestre¹, Pierre Charles², Loïc Guillevin³, Raphaël Porcher⁴ and Benjamin Terrier³, ¹cochin Hospital, Paris, France, ²Institut Mutualiste Montsouris, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…
Abstract Number: 1080 • ACR Convergence 2022
Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
Florence Delestre¹, Pierre Charles², Loïc Guillevin³, Raphaël Porcher⁴ and Benjamin Terrier³, ¹cochin Hospital, Paris, France, ²Institut Mutualiste Montsouris, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁴Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…
Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee¹, Lauren Blazek² and Eveline Wu³, ¹The University of North Carolina Chapel Hill, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
Abstract Number: 0436 • ACR Convergence 2022
Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study
Julien Culerrier¹, Yann Nguyen², Omer Karadag³, Sule Yasar Bilge⁴, Tuba DEMIRCI YILDIRIM⁵, Tahir Saygin Öğüt⁶, Veli Yazisiz⁶, Cemal Bes⁷, Ayse Cefle⁸, Oznur Sadioglu Cagdas⁹, Ayten Yazici⁸, Andreas Kronbichler¹⁰, David Jayne¹⁰, Alexis Regent¹¹, Vitor Teixeira¹², Sylvain Marchand-Adam¹³, PIerre Duffau¹⁴, Saskia Oro¹⁵, Baptiste Andre¹⁶, Luminita Luca¹⁷, Sarah Lechtman¹⁸, Achille Aouba¹⁹, Celine Lebas²⁰, Amélie Servettaz²¹, Amandine Dernoncourt²², Marc Ruivard²³, Anne-Marie Milesi²⁴, Vincent Poindron²⁵, Patrick Jego²⁶, Roberto Padoan²⁷, Paolo Delvino²⁸, Frédéric Vandergheynst²⁹, Christian Pagnoux³⁰, Elaine Yacyshyn³¹, Peter Lamprecht³², Oliver Flossmann³³, Xavier Puéchal¹¹ and Benjamin Terrier¹¹, ¹Université Paris Cité, Paris, France, Paris, France, ²AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ³Hacettepe University, Ankara, Turkey, ⁴Eskişehir Osmangazi Üniversity, Eskisehir, Turkey, ⁵Dokuz Eylul University, İzmir, Turkey, ⁶Akdeniz University, Antalya, Turkey, ⁷Bahçeşehi University, Istanbul, Turkey, ⁸Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, ⁹Kocaeli University, Kocaeli, Turkey, ¹⁰University of Cambridge, Cambridge, United Kingdom, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ¹²Hospital de Faro, CHUA, Lisbon, Portugal, ¹³Tours University Hospital, Tours, France, ¹⁴CHU Bordeaux, Bordeaux, France, ¹⁵Assistance Publique - Hôpitaux de Paris., Paris, France, ¹⁶Hôpital de la Timone, Marseille, Marseille, France, ¹⁷CHU de Poitiers, Poitiers, France, ¹⁸CHU Nice, Nice, France, ¹⁹Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ²⁰CHRU Lille, Lille, France, ²¹CHU Reims, Reims, France, ²²CHU Amiens - Picardie, Amiens, France, ²³Clermont Ferrand University Hospital, Clermont-Ferrand, France, ²⁴Centre hospitalier de Vichy, Vichy, France, ²⁵Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁶CHU Rennes, Paris, France, ²⁷University of Padova, Padova, Italy, ²⁸Università di Pavia, Vercelli, Italy, ²⁹Professeur de Médecine Interne et Sémiologie médicale, Directeur de la Clinique de Médecine Interne Générale, Université Libre de Bruxelles, Bruxelles, France, ³⁰Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³¹University of Alberta, Edmonton, AB, Canada, ³²Department of Rheumatology University of Lübeck Ratzeburger Allee, Lübeck, Germany, ³³Royal Berkshire Hospital, Reading, United Kingdom
Background/Purpose: ANCA-associated vasculitides (AAV) induced by anti-thyroid drugs (ATD) is a well-known entity. However, characteristics, requirement for immunosuppressive agents and the risk of relapse remain…
Abstract Number: 0439 • ACR Convergence 2022
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
Lynn Fussner¹, David Cuthbertson², Peter Grayson³, David Jayne⁴, Carol McAlear⁵, Michael Walsh⁶, Katherine Siminovitch⁷, Ulrich Specks⁸ and Peter Merkel⁹, ¹The Ohio State University, Columbus, OH, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: There are multiple reasons to suspect that alpha-1 antitrypsin (A1AT) genotype impacts disease characteristics in ANCA-associated vasculitis (AAV). A1AT serves as the predominant endogenous…
Abstract Number: 0442 • ACR Convergence 2022
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Lilian Xu¹, Faten Aqeel¹, Ojaswi Tomar², Tingting Li² and Duvuru Geetha¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Washington University in St. Louis School of Medicine, St. Louis, MO
Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…
Abstract Number: 0453 • ACR Convergence 2022
Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis
Aman Sharma¹, Prateek Deo¹, Shankar Naidu², Joydeep Samanta³, Sakshi Mittal³, Kusum Sharma³, Ritambhra Nada³, Varun Dhir⁴, sanjay jain² and Ranjana Minz², ¹PGIMER, Chandigarh, India, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³PGIMER, Chandigarh, India, ⁴PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: The purpose of this study was to validate the recently published 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for…
Abstract Number: 0457 • ACR Convergence 2022
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
Jan Schirmer¹, Beatriz Sanchez-Alamo², Sara Monti³, Bernhard Hellmich⁴, David Jayne⁵ and Gunnar Tomasson⁶, ¹University Medical Center Schleswig-Holstein, Kiel, Germany, ²Lund University, Skåne University Hospital, Lund, Sweden, ³Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ⁴Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland
Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…
Abstract Number: 0416 • ACR Convergence 2021
Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis
Jason Springer¹ and Ryan Funk², ¹Vanderbilt University Medical Center, Franklin, TN, ²University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…
Abstract Number: 1032 • ACR Convergence 2020
Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)
Eva Rottmann¹, Jason Bankert², Andrea Berger², Lester Kirchner², Joseph Dewalle², Marissa Meissner³, Jason George², Ion Dan Bucaloiu², Jaya Prakash Sugunaraj², Sudheer Penupolu² and David Bulbin¹, ¹Geisinger Health System, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Danville
Background/Purpose: ANCA-associated vasculitis has a reported prevalence ranging from 3.2 to 9.1 cases per 100,000 individuals, but little is known of geographic variations. The aim of…
Abstract Number: 1417 • ACR Convergence 2020
Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study
Sara Thietart¹, Guillaume Beinse², Perrine Smets³, Alexandre Karras⁴, Carole Philipponnet⁵, Jean-François Augusto⁶, Khalil El Karoui⁷, Rafik Mesbah⁸, Dimitri Titeca Beauport⁹, Mohamed Hamidou¹⁰, Pierre-Louis Carron¹¹, Julien Campagne¹², Karim Sacre¹³, Pascal Cohen¹, Eric Liozon¹⁴, Claire Blanchard-Delaunay¹⁵, Alex Kostianovsky¹⁶, Christian Pagnoux¹⁷, Luc Mouthon¹, Loïc Guillevin¹⁸, Benjamin Terrier¹ and Xavier Puéchal for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ²Inserm UMR 1138, Centre de Recherche des Cordeliers, Paris, France, ³Department of Internal Medicine, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Gabriel-Montpied, Clermont Ferrand, France, ⁴Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, ⁵Department of Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, Clermont Ferrand, France, ⁶Department of Nephrology-Dialysis-Transplantation, CHU Angers, Angers, France, ⁷Department of Nephrology and Transplantation, Hôpital Universitaire Henri-Mondor, Creteil, France, ⁸Department of Nephrology, CH Boulogne-sur-Mer, Boulogne-Sur-Mer, France, ⁹Department of Nephrology, Amiens University Medical Center, Amiens, France, ¹⁰Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, ¹¹Department of Nephrology-Dialysis-Transplantation, CHU Grenoble-Alpes, Grenobles, France, ¹²Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, ¹³Département de Médecine Interne, Hôpital Bichat, APHP, Paris, France, ¹⁴Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, ¹⁵Department of Internal Medicine, CH, Niort, France, ¹⁶Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aeres, Argentina, ¹⁷Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁸Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) frequently occurs among older patients, with different clinical presentations than the younger. Little is known on the outcome of older patients…
Abstract Number: 1421 • ACR Convergence 2020
Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans
Luis Palomino¹, Angelo Gaffo², Sebastian Sattui³ and Dongmei Sun², ¹University of Alabama at Birmingham Hospital, Birmingham, AL ²University of Alabama at Birmingham, Birmingham, AL, ³Hospital for Special Surgery, New York, NY
Background/Purpose: ANCA-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA), affect mostly Caucasians of European descent. Clinical…
Abstract Number: 1430 • ACR Convergence 2020
The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis
Edouard Sayad¹, Tiphanie Vogel¹, David Moreno McNeill¹, Nahir Cortes-Santiago¹, David Spielberg¹, Kalyani Patel¹ and Manuel Silva Carmona¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Anca-associated vasculitis (AAV) is characterized by vascular inflammation in multiple organs. The diagnosis can be made clinically using a number of different criteria. The…
Abstract Number: 1438 • ACR Convergence 2020
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)
Jason Springer¹ and Ryan Funk², ¹University of Kansas Medical Center, Overland Park, KS, ²UNIVERSITY OF KANSAS, Kansas City, KS
Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].